13 Annual Report 2021 13 Annual Report 2021 Use of PARP inhibitor drugs expanded beyond BRCA patients Development of a sophisticated method to isolate exosomes for early detection Recruitment begins to test ARt in a clinical trial of high-risk women Discovery that shows ascites impacts on some drugs’ effectiveness 10th anniversary of the White Shirt Campaign Discovery of a potential early detection biomarker (autoantibody) Development of a novel technique to identify blood DNA patterns in ovarian cancer patients Development begins for a biomarker panel for early detection (multimarker exosome panel) Validation of three unique biomarkers in ovarian cancer (blood DNA patterns) Development of a novel discovery approach for early detection (blood protein biomarkers) Successfully advocated for $16.2 million MRFF funding for ovarian cancer early detection and prevention research ARt pilot data indicates excellent discrimination in determining early and late stage disease Multi-marker exosome panel is shown to detect early stage ovarian cancer with over 85% accuracy The Precision Medicine platform began analysing patient samples as a key step towards clinical trials Off the back of the State of the Nation Report, successfully advocated for an additional $25 million MRFF funding for early detection of four low survival cancers, including ovarian cancer Discovery of 259 candidate biomarkers for detection of early stage ovarian cancer 30-year UKCTOCS research project released findings indicating that their trialled screening methods were not sufficient to improve survival rates Progesterone shown to suppress early lesion growth in fallopian tubes Early detection trials in 500 women using a multivariate index assay and machine learning resulted in >90% accuracy in symptomatic patients Progress in improving immune cells’ ability to provide long-term disease control against recurrence 2017 2018 2019 2020 2021